Compare BLNK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | ADCT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | Switzerland |
| Employees | 594 | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 496.7M |
| IPO Year | N/A | 2020 |
| Metric | BLNK | ADCT |
|---|---|---|
| Price | $0.78 | $4.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $2.13 | ★ $7.60 |
| AVG Volume (30 Days) | ★ 5.7M | 1.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $106,631,000.00 | $75,209,000.00 |
| Revenue This Year | N/A | $10.36 |
| Revenue Next Year | $17.87 | $3.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $0.63 | $1.05 |
| 52 Week High | $2.65 | $4.80 |
| Indicator | BLNK | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 24.13 | 55.06 |
| Support Level | $1.24 | $3.15 |
| Resistance Level | $1.43 | $4.62 |
| Average True Range (ATR) | 0.09 | 0.40 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 0.88 | 77.98 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).